Skip to main content

ImmunoCellular Therapeutics Short Interest Ratio and Short Volume

+0.03 (+6.39 %)
(As of 05/13/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume10,933 shs
Average Volume6,605 shs
Market Capitalization$2.09 million
P/E RatioN/A
Dividend YieldN/A

Short Interest

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Short Interest Data

Current Short Volume100 shares
Previous Short Volume1,200 shares
Change Vs. Previous Month-91.67%
Dollar Volume Sold Short$0.00
Short Interest Ratio / Days to Cover0.0
Last Record DateSeptember, 30 2020
Outstanding Shares4,190,000 shares
Percentage of Shares Shorted0.00%
Today's Trading Volume10,933 shares
Average Trading Volume6,605 shares
Today's Volume Vs. Average65.53%

Short Interest Over Time

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/30/2020100 shares $0.00 -91.7%N/A0N/A

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Short Interest FAQ

speech bubbles
speech bubbles

What is ImmunoCellular Therapeutics' current short interest?

Short interest is the volume of ImmunoCellular Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 30th, investors have sold 100 shares of IMUCD short.

Is ImmunoCellular Therapeutics' short interest increasing or decreasing?

ImmunoCellular Therapeutics saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 100 shares, a decline of 91.7% from the previous total of 1,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does ImmunoCellular Therapeutics' short interest compare to its competitors?

0.00% of ImmunoCellular Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ImmunoCellular Therapeutics: ULURU Inc. (0.00%), Acura Pharmaceuticals, Inc. (0.00%), BetterLife Pharma Inc. (0.00%), Parnell Pharmaceuticals Holdings Ltd (0.00%), GlobeImmune, Inc. (0.00%), Kaya Holdings, Inc. (0.00%), Immune Therapeutics, Inc. (0.00%), Cotinga Pharmaceuticals Inc. (0.00%), BriaCell Therapeutics Corp. (0.00%), and Intellipharmaceutics International Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.91 billion), Aon plc ($3.68 billion), ViacomCBS Inc. ($2.95 billion), The Clorox Company ($2.92 billion), Analog Devices, Inc. ($2.35 billion), Uber Technologies, Inc. ($2.27 billion), Moderna, Inc. ($2.14 billion), The Kroger Co. ($2.14 billion), Datadog, Inc. ($2.00 billion), and Simon Property Group, Inc. ($1.85 billion). View all of the most shorted stocks.

What does it mean to sell short ImmunoCellular Therapeutics stock?

Short selling IMUCD is an investing strategy that aims to generate trading profit from ImmunoCellular Therapeutics as its price is falling. ImmunoCellular Therapeutics' stock is trading up $0.03 today. To short ImmunoCellular Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that ImmunoCellular Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against ImmunoCellular Therapeutics?

A short squeeze for ImmunoCellular Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMUCD, which in turn drives the price of the stock up even further.

How often is ImmunoCellular Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMUCD, twice per month. The most recent reporting period available is September, 30 2020.

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.